RE: Here's a thoughtRemember also that there are 9.5 million warrants from the October financing that can be exercised as well (and probably have been or certainly will be, given they are currently so far in the money).
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT") is pleased toannounce that it has closed the previously announced financing with J.F.Mackie & Company Ltd. ("J.F. Mackie"). Gross proceeds of $1,138,741were raised, which includes the partial exercise of an overallotmentoption, resulting in 9,489,507 Units (the "Units") being sold. The Unitswere sold to the public at a price of
.12 per Unit, with each Unitconsisting of one common share of SCT ("Common Share") and one commonshare purchase warrant ("Warrant"). Each Warrant is exercisable toacquire one additional Common Share at a price of
.15 per share for 12months from the closing date. A total commission of $91,099 (8% ofgross proceeds raised) was paid to J.F. Mackie in connection with thebrokered financing. Additionally, J.F. Mackie received 474,475 BrokerWarrants. Each Broker Warrant is exercisable to acquire one Common Shareat a price of
.12 per share for 12 months from the closing date."